Bristol Myers Squibb Presents Phase 1 Breakfree-2 Study Results

Bristol Myers Squibb disclosed interim safety and efficacy results from the multiple sclerosis cohorts of its Phase 1, single-arm, dose-escalation Breakfree-2 study of investigational zolacabtagene autoleucel.